GLP-1 Receptor Agonists (Ozempic, Wegovy) Gastroparesis Litigation

This emerging multidistrict litigation (MDL) involves claims from users of GLP-1 receptor agonist drugs, such as Ozempic, Wegovy, and Mounjaro, who allege they developed a severe medical condition known as gastroparesis, or "stomach paralysis." These drugs, wildly popular for diabetes management and weight loss, work by slowing down digestion, which helps control blood sugar and creates a feeling of fullness.

However, plaintiffs in the lawsuit claim that for some individuals, this effect is far more extreme and persistent, leading to a chronic condition where the stomach cannot empty itself properly. Symptoms include severe nausea, vomiting, abdominal pain, and malnutrition. The lawsuits allege that the drug manufacturers, Novo Nordisk and Eli Lilly, failed to adequately warn patients and the medical community about the risk of developing severe or long-lasting gastroparesis.